Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough.

MLA

Mollica, Veronica, et al. “Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in MRCC: When RECIST Is Not Enough.” Cancers, vol. 13, no. 14, July 2021. EBSCOhost, https://doi.org/10.3390/cancers13143492.

APA

Mollica, V., Brocchi, S., Dall’Olio, F. G., Marcolin, L., Paccapelo, A., Santoni, M., Rizzo, A., Montironi, R., Golfieri, R., Massari, F., & Ardizzoni, A. (2021). Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. Cancers, 13(14). https://doi.org/10.3390/cancers13143492

Chicago

Mollica, Veronica, Stefano Brocchi, Filippo Gustavo Dall’Olio, Laura Marcolin, Alexandro Paccapelo, Matteo Santoni, Alessandro Rizzo, et al. 2021. “Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in MRCC: When RECIST Is Not Enough.” Cancers 13 (14). doi:10.3390/cancers13143492.